# Evaluate the Effect of Tirazamine on Primary Liver Cancer.

> **NCT06848556** · PHASE1,PHASE2 · TERMINATED · sponsor: **Zhejiang Raygene Pharmaceuticals Co., Ltd** · enrollment: 16 (actual)

## Conditions studied

- Hepato Cellular Carcinoma (HCC)

## Interventions

- **DRUG:** tirapazamine
- **PROCEDURE:** Transarterial Embolization
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT06848556
- **Lead sponsor:** Zhejiang Raygene Pharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-05-14
- **Primary completion:** 2023-11-06
- **Final completion:** 2023-11-20
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Company Operational Strategy Adjustment
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06848556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06848556, "Evaluate the Effect of Tirazamine on Primary Liver Cancer.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06848556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*